Cyclacel's 15min chart indicates Bollinger Bands expanding upward, bullish Marubozu signals.

According to Cyclacel's 15-minute chart, the Bollinger Bands are expanding upward, indicating a bullish trend driven by strong buying pressure. The recent Bullish Marubozu candlestick pattern observed on September 11, 2025 at 10:30 further supports this bullish momentum, suggesting that buyers are firmly in control of the market.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), a micro-cap biotech company with a market capitalization of $15.41 million, has seen its shareholders approve several key proposals at a recent special meeting. The meeting, held via live audio webcast, saw shareholders vote in favor of authorizing the issuance of Cyclacel common stock to Fitters Parent, as outlined in the Exchange Agreement. This proposal received 1,095,988 votes in favor, representing 58.8% of shares voted, with 6,691 votes against and 131 abstentions Cyclacel Pharmaceuticals shareholders approve share issuance and name change^[1].

Additionally, shareholders approved a proposal to authorize the potential issuance of more than 20% of the company’s outstanding common stock, complying with Nasdaq Listing Rule 5635(a). This proposal also received 1,095,986 votes in favor (58.8%), 6,664 against, and 160 abstentions. Furthermore, shareholders approved an amendment to Cyclacel’s certificate of incorporation to change the corporate name to Bio Green Med Solution, Inc. This measure received 1,097,489 votes for (58.9%), 5,151 against, and 170 abstentions Cyclacel Pharmaceuticals shareholders approve share issuance and name change^[1].

The special meeting was conducted virtually and the results were disclosed in a press release statement filed with the Securities and Exchange Commission. Cyclacel Pharmaceuticals is listed on the Nasdaq Capital Market under the ticker CYCC.

Technical analysis of Cyclacel’s stock suggests a bullish trend. According to a 15-minute chart, the Bollinger Bands are expanding upward, indicating strong buying pressure. The recent Bullish Marubozu candlestick pattern observed on September 11, 2025 at 10:30 further supports this bullish momentum, suggesting that buyers are firmly in control of the market .

Despite the positive shareholder votes and technical indicators, Cyclacel Pharmaceuticals continues to face challenges. The company is currently overvalued, with shares down nearly 92% year-to-date. However, the company maintains a healthy current ratio of 5.77, though its overall financial health score indicates weakness Cyclacel Pharmaceuticals shareholders approve share issuance and name change^[1].

In other recent news, Cyclacel Pharmaceuticals has made several significant announcements. The company filed an 8-K report with the Securities and Exchange Commission, submitting audited consolidated financial statements for the quarter ending March 31, 2025. Additionally, Cyclacel appointed SFAI Malaysia PLT as its new auditor following the dismissal of Bush & Associates CPA LLP. The change in auditors was approved by the Audit Committee of Cyclacel’s Board of Directors. Furthermore, Cyclacel held its 2025 annual meeting of shareholders, where five directors were re-elected to serve three-year terms and shareholders approved changes to the company’s equity plan Cyclacel Pharmaceuticals shareholders approve share issuance and name change^[1].

Investors should closely monitor Cyclacel Pharmaceuticals’ ongoing developments and technical indicators to make informed investment decisions.

Cyclacel Pharmaceuticals shareholders approve share issuance and name change^[1]: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), https://ca.investing.com/news/sec-filings/cyclacel-pharmaceuticals-shareholders-approve-share-issuance-and-name-change-93CH-4192186
: Cyclacel Pharmaceuticals 15-minute chart, September 10, 2025